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Abstract
Background: Myxoma virus is a member of the Poxviridae and causes disease in European rabbits. Laboratory
confirmation of the clinical disease, which occurs in the autumn of most years in Denmark, has been achieved
previously using antigen ELISA and electron microscopy.
Results: An unusually large number of clinically suspected cases of myxomatosis were observed in Denmark
during 2007. Myxoma virus DNA was detected, using a new real time PCR assay which targets the M029L gene, in
over 70% of the clinical samples submitted for laboratory confirmation. Unexpectedly, further analysis revealed that
a high proportion of these viral DNA preparations contained a frame-shift mutation within the M135R gene that
has previously been identified as a virulence factor. This frame-shift mutation results in expression of a greatly
truncated product. The same frame-shift mutation has also been found recently within an avirulent strain of
myxoma virus (6918). However, three other frame-shift mutations found in this strain (in the genes M009L, M036L
and M148R) were not shared with the Danish viruses but a single nucleotide deletion in the M138R/M139R
intergenic region was a common feature.
Conclusions: It appears that expression of the full-length myxoma virus M135R protein is not required for
virulence in rabbits. Hence, the frame-shift mutation in the M135R gene in the nonpathogenic 6918 virus strain is
not sufficient to explain the attenuation of this myxoma virus but one/some of the other frame-shift mutations
alone or in conjunction with one/some of the thirty two amino acid substitutions must also contribute. The real
time PCR assay for myxoma virus is a useful diagnostic tool for laboratory confirmation of suspected cases of
myxomatosis.
Background
Myxomatosis is a disease primarily of European rabbits
and is caused by infection with myxoma virus which
can result in very high levels of mortality (nearly 100%).
In consequence, the virus has been deliberately intro-
duced into some countries as a control measure for wild
rabbit populations. Although effective initially, co-evolu-
tion of virus and the rabbit population has resulted in
the generation of attenuated field strains of the virus
and also virus-resistant populations of wild rabbits [1-3].
Infection by myxoma virus of pet rabbits (and pre-
sumably wild rabbits too) within Denmark occurs on a
regular basis particularly during September and Octo-
ber of each year and it is a notifiable disease. When
infection has been suspected clinically by veterinarians,
tissue samples from dead or euthanized animals have
been submitted to the Danish National Veterinary
Institute (DTU Vet) and laboratory diagnosis has been
performed using ELISA based systems and/or electron
microscopy. The number of cases and suspicions in
each year is normally small but, unexpectedly, in 2007
there was a large increase in the number of clinical
cases of myxomatosis observed within Denmark (see
below and Table 1).
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genus within the Poxviridae (see [3]). The virus has a
dsDNA genome of about 160,000 bp and the complete
sequence of the virulent Lausanne strain has been deter-
mined [4]. The presence of numerous genes encoding
immunomodulatory proteins and the narrow host range
of the virus has made it an attractive system for analys-
ing the role of these immunomodulators in pathogenesis
[3,5]. Poxviruses encode a variety of proteins that block
host interferon and tumor necrosis factor mediated anti-
viral responses. Some of these proteins act within the
cell, these include the vaccinia virus E3L and K3L pro-
teins (plus their homologues from other viruses) that
inhibit the double-stranded RNA activated protein
kinase (PKR)-induced phosphorylation of the eukaryotic
translation initiation factor 2 (eIF2) (reviewed in [6]).
Other viral proteins act at the cell surface, for example,
myxoma virus encodes a protein, called M-T7, which
inhibits the interaction of interferon-g with its cellular
receptor [7]. Recently, the product of the myxoma virus
M135R gene has been identified as a novel cell surface
virulence factor [8]. The M135R protein, which is glyco-
sylated, has some similarity (23% identity) to the vacci-
nia virus B18R protein which acts as an interferon-a/b
receptor. Studies have shown, however, that the M135R
p r o t e i n ,w h i c hi sm u c hs h o r t er than the vaccinia virus
B18R product, does not function in this way [8]. How-
ever, this same study showed that targeted deletion of
the M135R gene (removing 86% of the coding sequence)
severely attenuated the virus in European rabbits, with
all inoculated animals recovering from the moderate
symptoms.
The availability of the myxoma virus genome sequence
([4], [GenBank:NC_001132]) enabled the design of a
sensitive and specific real-time PCR-based assay for this
virus. This assay has been used to identify the presence
of myxoma virus DNA from within laboratory and clini-
cal samples. Furthermore, sequence analysis of selected
regions of these myxoma viruses has been performed to
explore the relationship between current Danish viruses
and other virulent and attenuated virus strains. Surpris-
ingly, a high proportion of the Danish samples, obtained
from clinically diseased animals, contained a frame-shift
mutation within the M135R gene, which severely trun-
cates the expressed protein product.
Methods
Viral DNA isolation
Cell culture grown samples of myxoma virus, vaccinia
virus (WR strain), swinepox and Orf virus or rabbit tis-
sue homogenates were used to prepare samples of viral
DNA for analysis. The tissues (including nose, lips, eye-
lids and kidneys) from dead or euthanized pet rabbits
which had exhibited clinical disease and had been pro-
vided for laboratory diagnosis, were homogenized in
physiological saline (1 ml/g of tissue) and then clarified
by centrifugation. The DNA was isolated using the
QIAamp DNA Blood Mini kit (Qiagen) using the “Blood
and Body Fluid Spin protocol” as described by the man-
ufacturer. Briefly, supernatant samples (200 μl) were
incubated with Qiagen protease at 56°C for 10 mins,
mixed with an equal volume of ethanol and applied to
the QIAamp Spin columns. Bound DNA was eluted in
water (50 μl) and then assayed directly. It was found
that using 1 μl of the eluted DNA was optimal in the
real time PCR assay described below, for some samples
higher amounts could produce a lower signal, presum-
ably due to the presence of some inhibitor.
In addition, viral DNA was isolated, as described
above, from a sample of Cunivak vaccine (supplied from
Impfstoffwerk Dessau-Tornau GmbH, Germany) which
contains a live attenuated strain of myxoma virus.
Quantitative real-time PCR detection assay
The genome sequence of the Lausanne strain of myx-
oma virus [4] was used as the basis for primer and
probe design for a real time PCR assay for detection of
the viral DNA. This assay targeted the M029L gene (nt
29307- 28963), which is the homologue of the vaccinia
virus E3L gene. The primers (myxE3Lfor with myxE3L-
rev) and the MGB probe (SwinemyxE3LCOMP) are
listed in Table 2. The PCR was designed to amplify a
fragment of 119 bp (see Figure 1a). The assays were per-
formed using the TaqMan Universal Mastermix
(Applied Biosystems). Briefly, the samples were treated
with uracil-N-glycosylase (UNG) at 50°C for 2 min, fol-
lowed by incubation at 95°C for 10 min to inactivate the
UNG and to activate the TaqGold. Amplification was
achieved using 50 cycles of incubation at 95°C for 15
Table 1 Analysis of suspect myxomatosis samples sub-
mitted for laboratory analysis in Denmark in the period
1998-2007
Year Number of
submissions
Number of positive
a
submissions (%
positive)
2007 195 142 (73%)
2006 3 2 (67%)
2005 3 1 (33%)
2004 4 2 (50%)
2003 7 5 (71%)
2002 3 2 (67)
2001 3 0 (0%)
2000 8 2 (25%)
1999 6 1 (17%)
1998 15 11 (73%)
a Samples were tested by ELISA and/or electron microscopy during the period
1998-2006 (26 of 52 samples proved positive during this period) and in 2007
the samples were analysed using the real time PCR assay described here.
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cence was measured after each cycle in a Stratagene
MX4000 or MX3005 quantitative PCR thermocycler and
the results were analysed using the MxPro software. Pri-
mers were purchased from DNA Technology A/S (Riss-
kov, Denmark) while MGB probes were obtained from
Applied Biosystems. To assess the sensitivity of the real
time PCR assay for myxoma virus DNA, the fragment of
the myxoma genome including the entire myxoma virus
M029L gene was amplified in a standard PCR using a
myxoma virus DNA preparation with the primers
MyxM029Lfor and MyxM029Lrev (see Table 2), the
product (409 bp) was inserted into pCR-XL-TOPO
(Invitrogen) as described by the manufacturer. Plasmid
DNA containing the amplified sequence was isolated,
quantified (by spectrophotometry) and then a 10-fold
dilution series (from 10
7 to 10
1 copies per μl) was pre-
pared and assayed as above.
Sequence comparison of the M135R gene from myxoma
virus isolates
A standard PCR was performed using the isolated viral
DNA preparations from a variety of different myxoma
virus samples with the primers M135Rfor and
M135Rrev (Table 2) which had been designed to amplify
t h ee n t i r ec o d i n gs e q u e n c eo ft h eM 1 3 5 Rg e n e( n t
131699-132235) plus some flanking sequences. The
amplicons obtained (653 bp) were purified and
sequenced, in both directions, using the same primers
on an ABI 3130 automatic sequencer with a BigDye
Terminator v3.1 Cycle sequencing kit (Applied Biosys-
tems). The sequences were initially analysed using Bio-
Numerics (Applied-Maths) software and the fasta files
were then aligned with the myxoma virus sequence
[GenBank:NC_001132] using ClustalW2 [9].
Expression analysis of M135R proteins
Analysis of M135R protein expression was achieved by
making fusion constructs between the coding sequence
for chloramphenicol acetyl transferase (CAT) and the
M135R coding sequence. The CAT sequence was ampli-
fied in a standard PCR using primers CATBamfor and
CATXSrev (Table 2) using a derivative of pSV2CAT
[10] as template. These primers introduced BamHI,
XhoI and SalI restriction sites plus an in-frame termina-
tion codon following the XhoI site. The product (739
bp) was inserted into pCR-XL-TOPO (Invitrogen). From
the resulting plasmid, BamHI-XhoI and BamHI-SalI
fragments were prepared and ligated into a BamHI-XhoI
digested derivative of pGEM3Z (Promega) containing a
modified polylinker, (T7-BamHI-SmaI-XhoI-EcoRI-
ApaI-SalI, as described [11], to produce pGEMCATBS
and pGEMCATBX respectively. The former plasmid
includes a termination codon at the end of the CAT
sequence while the latter does not. The myxoma M135R
sequences were amplified from various different myx-
oma virus DNA samples using the primers
M135RXFOR and M135RAPAREV (Table 2) which pro-
duced a product of 559 nt including the complete cod-
ing sequence of the M135R gene flanked by XhoI and
ApaI sites. The products were individually inserted into
pCR-XL-TOPO and then XhoI-ApaI fragments were
isolated and ligated into similarly digested pGEM-
CATBX (as described above) to produce a fused open
reading frame including the CAT and M135R coding
sequences. Structures of these plasmids (see below) were
confirmed by enzyme digestion and sequence analysis.
These plasmids were assayed by transfection into BHK
cells that had been infected with the recombinant vacci-
nia virus vTF7-3 [12] essentially as described previously
[13] except that FuGene 6 (Roche) was used rather than
lipofectin (see [11]). The vaccinia virus vTF7-3 expresses
the T7 RNA polymerase and generates capped mRNAs
from the transfected plasmids. Cell extracts were pre-
pared 20 h post transfection and analysed by SDS-PAGE
and immunoblotting. Expression of CAT and the CAT-
M135R fusion proteins was detected using rabbit anti-
CAT antibodies (Sigma) and peroxidase labelled anti-
Table 2 Oligonucleotide primers and probes used in this
work
Primers Sequence (5’-3’)
myxE3Lfor TAACAACCGCCGTAAATGTG
myxE3Lrev GCAAACCAAAAATCCGTGTAC
MyxM029Lfor GTTGGTAATTTCATTTCGTACCA
MyxM029Lrev GGTAAACAATTAATCCGTTGTAA
M135Rfor CCATACAGAAAGAGATTCAGTTGGA
M135Rrev GGAGTCTGTATACAGTGATAAATCCTT
M135RXFOR CCCTCGAGATAAACATGGTGTTTATATTTATTATC
M135RAPAREV TTGGGCCCTTACAGGACGCCTAAGGATATC
CATBamfor TAGGATCCGGGATGGAGAAAAAAATCACTGG
CATXSrev CCGTCGACTTACTCGAGCGCCCCGCCCTGCCACTC
M138Lfor TTAGGAAGATGTCCAGGAATC
M139Rrev CCGTATTTGTTCGGCAGACC
M153Rfor GTGTATAGACTGTCGTACCTAC
M154Rrev ACGGCAATCAACTTCCCGAC
M009Lfor CAACTGGGATTTCTGCGTAC
M009Lrev GACGTAATGCGTCGGCGTG
M036Lfor CAACAGAACGGCAACAATTTATGT
M036Lrev ACGTGCAGTAACGCCTGTTC
M148Rfor CGACCATCTGATAATGTATGTC
M148Rrev ACAGGGATCGAGAGTGAACG
Probe
SwinemyxE3LCOMP 6FAM-CTCAACGAATATTGTCAGATTA-MGBNFQ
Added restriction enzyme sites within the primer sequences are underlined
and nucleotides corresponding to the initiation and termination codons
within the M135R and CAT sequences are indicated by bold italics.
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Plus, GE Healthcare).
PCR amplification and sequence analysis of other
myxoma virus regions
In addition to the M135R gene, five other regions of the
myxoma virus genome were amplified by PCR using pri-
mers flanking the insertions and deletions identified
within a nonpathogenic myxoma virus strain (6918) by
Morales et al. [14]. The primers, listed in Table 2, were
designed to amplify a fragment of about 400-500 bp in
each case to permit analysis of the M138L/M139R and
M153R/M154R intergenic regions plus the coding
regions from the M009L, M036L and M148R genes.
Amplicons were gel purified and sequenced (by Agowa,
Germany) in both directions using the primers used for
the PCRs.
Results
Design and use of a real time quantitative PCR assay for
detection of myxoma virus
A real time quantitative PCR (qPCR) assay to detect
specifically myxoma virus DNA was designed. The
Figure 1 Design and properties of myxoma virus specific qPCR assay. Panel (a). The sequence of the myxoma virus M029L gene [GenBank:
NC_001132] was aligned with the homologous E3L genes from vaccinia virus (WR strain, [GenBank:AY243312], swinepox [GenBank:NC_003389]
and Orf virus [GenBank:NC_005336]) using ClustalW2. The positions of the myxoma virus specific primers (myxE3Lfor and myxE3Lrev) (in bold
type and underlined) and the MGB-probe (within the rectangle) which recognizes a sequence that is identical in myxoma virus and swinepox
virus are indicated. Panel (b). Viral DNA was prepared from cell culture grown samples of vaccinia virus (WR strain, blue diamond), myxoma virus
(red triangle), swinepox virus (black square) and Orf virus (black circle) and each was assayed (in parallel and with negative (water) controls
(yellow and green symbols)) in the qPCR assay for myxoma virus as described in Materials and Methods. Panel (c) Serial 10-fold dilutions of a
plasmid, including the myxoma M029L gene, containing between 10
1 and 10
7 copies were tested in the myxoma virus assay. The gradient of
the line is -3.293 and the efficiency of the PCR reaction was calculated as 101.2%.
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genome together with the homologous sequences from
vaccinia virus (Orthopoxvirus), swinepox (Suipoxvirus)
and Orf virus (Parapoxvirus)a r es h o w ni nF i g u r e1
(panel a). The probe is identical to a region of the myx-
oma virus M029L gene and also to part of the E3L
homolog within swinepox virus (SPV032), however the
primer sequences selected to amplify the myxoma virus
DNA are very different from the corresponding
sequences in swinepox virus. The myxoma probe
sequence is significantly different from the correspond-
ing region of the vaccinia virus E3L sequence (7 nt dif-
ferences out of 22) and from the Orf virus E3L homolog
(only 13 nt of the Orf virus sequence match the myx-
oma virus probe).
To characterize the system for the detection of myx-
oma virus DNA, viral nucleic acid was prepared from cell
culture grown samples of myxoma virus, vaccinia virus,
swinepox and Orf virus and tested in the qPCR assay. As
expected the assay efficiently detected the myxoma virus
DNA but did not produce a signal using nucleic acid pre-
parations from cells infected with the other poxviruses
tested (see Figure 1, panel b). As controls, analogous
qPCR assays for orthopoxviruses (HA gene, as described
previously [15]) and parapoxviruses (B2L gene, encoding
the major envelope protein, as described [16]) respec-
tively were also performed. These assays correctly
detected their target viruses within these samples, as
expected, but did not detect the myxoma virus DNA
(data not shown). The qPCR assay for myxoma virus
amplified a fragment of 119 bp (including the primer
sequences) and this product could be detected by agarose
gel electrophoresis at the end of the assay (data not
shown) as well as by the change in fluorescence mea-
sured in the assay (Figure 1, panel b). To determine the
sensitivity of the myxoma virus assay, a region of the
myxoma virus genome (409 bp, containing the entire
M029L gene) was amplified by PCR from a viral DNA
preparation and inserted into a plasmid vector. The
resultant purified plasmid was quantified and a dilution
series was then prepared and assayed in the qPCR to pro-
duce a standard curve (see Fig. 1, panel c). This showed
that the assay could detect as little as 10 copies of the
myxoma virus sequence in each sample and produced a
linear response up to 10
7 copies per assay. Thus the assay
has a wide range of sensitivity. The specificity of the assay
for myxoma virus DNA was confirmed using conven-
tional PCR assays, which targeted other regions of the
myxoma virus genome, on DNA preparations from clini-
cal and laboratory samples (see below).
The qPCR assay for myxoma virus has also been
applied to 195 tissue samples from dead or euthanized
rabbits which had displayed clinical signs of myxomato-
sis and were submitted by veterinarians to DTU Vet at
Lindholm during 2007. From these samples, 142 (73%)
proved to be positive (see Table 1) indicating that clini-
cal suspicion had been accurate in most cases. Indeed,
most of the clinical samples assayed produced a very
high signal (Ct values less than 20). The great increase
in the number of samples submitted for laboratory diag-
nosis is unrelated to the method used for the diagnosis
but reflects an exceptional incidence of disease during
2007.
Comparison of myxoma virus isolates by sequence
analysis of the M135R gene
The region of the myxoma virus M029L gene amplified
in the diagnostic qPCR assay is quite short (119 bp). In
order to obtain some indication of whether all the cases
of myxomatosis in Denmark during 2007 were caused by
the same strain of virus, the sequence of a larger region
of the genome, from 13 selected samples, was examined.
For this purpose, the M135R gene was chosen as a target
s i n c ei th a dr e c e n t l yb e e nr e p o r t e dt ob ea ni m p o r t a n t
virulence factor [8]. The DNA preparations from these
different clinical samples (which had each been shown to
contain high levels of myxoma virus DNA using the
qPCR assay described above) plus samples from a myx-
oma vaccine (Cunivak) and a tissue culture grown sample
of myxoma virus were used as the template in standard
PCRs to amplify the gene encoding the M135R protein.
Each of the tested clinical samples, as well as the vaccine
and the cell culture grown virus, generated the expected
product in this analysis, supporting the specificity of the
qPCR assay which had targeted a completely different
region of the genome. The amplified products (ca.650
bp) were then sequenced using the primers used for the
PCR reaction (see Figure 2, panel a). The PCR products
obtained from the commercial myxoma vaccine and
from three of the clinical samples (which each originated
from Lolland in south-eastern Denmark, e.g. sample
8770, see Table 3) had sequences which are identical to
t h ep u b l i s h e dm y x o m av i r u sM 1 3 5 Rg e n es e q u e n c e[ 4 ] .
A sample obtained from an archived cell culture grown
virus had a single nt substitution (C to T) which encoded
a change of amino acid residue 141 from His (H) to Tyr
(Y). However, unexpectedly, the ten other recent Danish
samples analysed, predominantly obtained from different
locations in Eastern Denmark around Copenhagen, each
had the same single nucleotide insertion within the
M135R coding sequence compared to the published
sequence. This mutation resulted in a run of 5 G’s being
expanded to 6 G’s and this insertion was very clear in the
original sequence traces (see Figure 2, panels b and c).
This sequence change results in a shift in reading frame
after the translation of amino acid residue 19 (out of a
total of 178 residues for the wt protein). The frame-shift
is predicted to result in protein synthesis termination
after a total of 40 codons have been translated. The
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be comprised of amino acid residues decoded in a differ-
ent reading frame from the wt protein (see Figure 2,
panel a).
Analysis of M135R protein expression from amplified
M135R gene sequences
On the basis of the sequencing data, it was apparent
that DNA fragments containing the insertion of a single
nucleotide within the M135R coding sequence should
encode a very different protein than the wt sequence
(see Figure 2, panel a). In order to confirm that this sin-
gle nucleotide insertion was not a sequencing or PCR
artefact, new independent PCR products derived from
the viral DNA preparations were made using different
primers (M135RXFOR and M135RAPAREV, see Table
2). Sequencing of these new amplicons confirmed the
presence of the single G insertion in the majority of the
Danish field samples analysed (data not shown). These
primers were also designed to allow the fusion of these
amplified myxoma virus sequences downstream of the
CAT coding sequence (lacking a termination codon, as
in pGEMCATBX, see Figure 3) in order to express
CAT-M135R fusion proteins.
It was anticipated that the construction of plasmids
containing the fused CAT-M135R reading frames should
allow the expression of the normal M135R coding
sequence to be observed and, more importantly, also the
prematurely terminated M135R gene product which by
itself would only be 40 amino acids in length, ca. 4.5 kDa,
and therefore difficult to detect alone. Different plasmids
containing either the wt M135R sequence (e.g. as in the
myxoma vaccine) or the frame-shift variant (+G) were
constructed and then assayed along with a plasmid
encoding the normal CAT coding sequence (see Figure
3). The CAT vectors, pGEMCATBS and pGEMCATBX
(both lacking any M135R sequences) very efficiently
expressed the CAT protein (about 27 kDa) as expected
(Figure 3, panel B). Fusing the wt M135R sequence to the
CAT coding sequence (as in plasmid pCATM135Rwt)
resulted in the expression of a much larger protein being
recognized by the anti-CAT antibodies consistent with
the expected fusion product of ca. 45 kDa (Figure 3,
panel B, lanes 3 and 4). In contrast, the attachment of the
mutant M135R sequences (as in pCATM135R+G), con-
taining the insertion of a single G nt, resulted in a small,
albeit readily detectable, decrease in the mobility of the
CAT protein (Figure 3, panel B, lanes 5 and 6) consistent
with the predicted addition of only an extra 40 amino
acid residues (ca. 4.5 kDa) to the C-terminus of CAT. In
addition, a smaller, weak band, ca. 22 kDa, was also
detected from this plasmid, it seems likely that this is a
degradation product derived from the fusion protein
which may adopt a partially unfolded structure.
PCR and sequence analysis of Danish samples of myxoma
virus DNA
Very recently Morales et al. [14] have published the com-
plete genome sequence of a nonpathogenic field strain
(6918) of myxoma virus isolated in Spain. This sequence
was found to be 99.95% identical to the virulent Lau-
sanne strain but the 6918 virus only produces moderate
symptoms in inoculated animals and even milder disease
in animals infected by contact [17]. In comparison to the
parental virus, the 6918 strain had 32 amino substitutions
and also four genes were interrupted by frame-shift
mutations. Remarkably, one of these frame-shift muta-
tions (in M135R) was identical to the insertion detected
in most of the Danish samples analysed here. Thus it was
decided to analyse four of the Danish samples, each con-
taining the frame-shift mutation within the M135R gene,
for the presence of the other insertions/deletions
detected in the nonpathogenic strain 6918. Fragments of
ca. 400-500 bp corresponding to five separate regions of
t h eg e n o m ei n c l u d i n gt h ei n t e r g e n i cr e g i o n sM 1 3 8 L /
M139R and M153R/M154R plus part of the coding
Table 3 Comparison of insertions/deletions within the nonpathogenic Spanish 6918 myxoma virus strain and Danish
clinical samples
Country of origin/sample
ES***
1 DK
2 DK DK DK DK
Locus Lausanne (wt) Strain 6918 (mut) 7889 8605 8620 8773 8770 Cunivak
M135R TGTGGGGGTG TGTGGGGGGTG (+G) mut mut mut mut wt wt
M009L TCCATCGACATCCA TC-CA (-CATCGACATC) wt wt wt wt wt n.d.*
M036L ACCCCCAGT ACCCCCCAGT (+C) wt wt wt wt wt n.d.*
M148R ACCCCCCTTC ACCC-CCTTC (-C) wt wt wt wt wt ** wt**
M138L/M139R ATTTTTTTTGTG ATTT-TTTTGTG (-T) mut mut mut mut wt wt
M153R/M154R CTTTTTTTTAAC CTTT-TTTTAAC (-T) wt wt wt wt wt mut
* n.d. = not determined since no PCR product was obtained
** two separate single point mutations within this coding sequence were observed, one of which was common to the sequences of the Cunivak and 8770
samples.
*** data from [14]
1: ES = Spain
2: DK = Denmark
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amplified by PCR, using primers listed in Table 2, and
s e q u e n c e d .T h er e s u l t sa r es h o w ni nT a b l e3 .W ea l s o
selected for these analyses one clinical sample (8770) and
the Cunivak vaccine strain, which had the wt M135R
gene sequence. From the thirty new PCR reactions, the
expected products were obtained in all but two cases, no
products were detected using the Cunivak DNA with the
primers targeting the genes M009L and M036L, presum-
ably sequence differences were present at the primer
binding sites. For the samples containing the single
nucleotide insertion within the M135R gene, the
sequences of the M009L, M036L, M148R and M153R/
M154R fragments were identical to the virulent Lausanne
sequence. However, each of these samples lacked a single
nucleotide within the M138L/M139R intergenic region
as was found for the 6918 strain. The 8770 sample (with
the wt M135R gene) had the wt M138L/M139R inter-
genic sequence and also shared a single point mutation
within the M148R coding sequence with the Cunivak
sample.
Discussion
A rapid, sensitive and specific quantitative PCR assay
has been developed for myxoma virus which comple-
ments previously described qPCR assays for orthopox-
viruses (e.g. vaccinia virus, [15]) and parapoxviruses (e.g.
Orf virus, [16]). This assay has been shown to function
on tissue culture grown viruses and also directly on
material extracted from clinical samples. It removes the
requirement for specific antisera (which can be variable)
or an electron microscope.
Figure 2 Evidence for a frame-shift mutation within the M135R gene from Danish samples of myxoma virus. Panel (a). The nucleotide
sequence of the myxoma virus M135R gene, plus flanking sequences, is shown. Primers M135Rfor and M135Rrev (see Table 2), indicated in bold
italics, were used to amplify by PCR the M135R gene, together with some flanking sequences at both termini, and these fragments were
sequenced directly. The myxoma virus sequences included in primers M135RXFOR and M135RAPAREV (Table 2) for amplifying the coding
sequence for M135R are underlined. The initiation and termination codons within these primers are indicated in bold capitals. The region of the
gene in which a frame-shift mutation was present in certain virus samples is indicated within a rectangle. Panels (b) and (c.) Sequence traces
obtained by analysis of a wt M135R gene sequence (as in the myxoma vaccine, panel (b)) and the mutant (+G) form (panel (c)) found in the
majority of Danish clinical samples in 2007. The region shown corresponds to the portion of the sequence contained within the rectangle in panel
(a). The region of the M135R gene which is predicted to be translated in a different reading frame, downstream of the insertion of a G nucleotide,
is indicated in red in panel (a). The termination codons (TAA) for the wt and mutant M135R gene products are indicated in bold capitals.
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from Danish rabbits with clinically determined myxoma-
tosis and we confirmed the diagnosis of the unusually
large number of cases of myxomatosis in Denmark dur-
ing 2007 (see Table 1). The cases were predominantly
located in the eastern part of Denmark around Copen-
hagen, however a small number of cases were also
observed elsewhere (as in most previous years). Unex-
pectedly, a specific frame-shift mutation was present
within the coding sequence of the M135R gene in most
of the current Danish samples. The insertion of a single
additional G, into a run of 5 G’s, was present in 10 out
of 13 samples analysed. This was the only sequence dif-
ference in the M135R gene between each of these sam-
ples and the myxoma virus vaccine (which is also
identical in this gene to the pathogenic Lausanne strain,
[4]). The same nucleotide insertion was also detected in
subsequent, independent, PCR reactions which used a
different primer set. The generation of these amplicons
enabled the fusion of the various M135R gene sequences
to the coding sequence of the CAT gene (lacking a ter-
mination codon). Expression of these fusion gene plas-
mids within mammalian cells, in transient expression
assays, provided clear evidence that the frame-shift
mutation, as detected by the DNA sequencing, indeed
resulted in the synthesis of a greatly truncated protein
from the mutant M135R sequence (Figure 3).
The M135R gene has recently been described as a viru-
lence factor in myxoma virus [8] since targeted deletion
(removing 86% of the coding region) of the gene resulted
in severe attenuation of the virus within European rab-
bits. Experimental inoculation of rabbits with the modi-
fied virus gave rise to only moderate symptoms and all
animals survived whereas all animals receiving viruses
with the intact M135R gene developed severe disease and
had to be euthanized. Hence it was surprising that viral
DNA obtained from rabbits with clinical disease encoded
a greatly truncated version of this gene product
Figure 3 Effect of the frame-shift mutation on expression of the M135R gene product. Panel (a). CAT-M135R fusion genes were
constructed to demonstrate the effect of the +G insertion within the M135R gene on protein expression. Plasmids containing either the wt
(pCATM135Rwt) or the frame-shift variant (pCATM135R+G) of the M135R sequence were constructed. The expected products from the plasmids
containing just the CAT open reading frame (ORF) (i), the CAT ORF fused to the wt M135R ORF (ii) and CAT fused to the mutant M135R+G
sequence (iii) are illustrated. Panel (b). The plasmids shown in panel (a) were transfected into BHK cells that had been infected with the
recombinant vaccinia virus vTF7-3 which expresses the T7 RNA polymerase. Cell extracts were prepared 20 h later and analysed by SDS-PAGE
and immunoblotting using rabbit anti-CAT antibodies. Detection was achieved using peroxidase-labelled anti-rabbit IgG and chemiluminescence
reagents with a BioRad Chemidoc XRS. Lane 1, pGEMCATBX (without a termination codon at the end of CAT but translation terminates within
the vector sequence); lane 2, pGEMCATBS (with a termination codon, see panel (a)); lanes 3 and 4, plasmids (pCATM135Rwt) containing the
fused CAT and wt M135R ORFs (n.b., there is no termination codon at the end of the CAT sequence); lanes 5 and 6, plasmids (pCATM135Rwt+G)
containing the fused CAT and mutant M135R+G sequences and lane 7, No DNA (negative control). The migration of molecular weight markers is
indicated. The products corresponding to those expected from constructs (i), (ii) and (iii) shown in panel (a) are marked.
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Page 8 of 10comprising only 19 (out of the total 178) amino acids
(plus 21 residues translated in a different reading frame).
Clearly, the presence of this frame-shift mutation does
not severely attenuate the virus within rabbits, since the
samples analysed came from animals which had died or
were showing significant clinical disease which had lead
veterinarians to euthanize the animals. This result is not
without precedent. Initial studies, using gene deletion,
aimed at determining whether particular poxvirus genes
were essential for growth indicated that the vaccinia virus
F11L gene was essential for growth [18], however this
gene is split in the modified vaccinia Ankara strain indi-
cating that the intact gene is not essential [19]. Subse-
quent studies using an improved approach demonstrated
that this gene is indeed non-essential and showed that
misleading results can be obtained from the use of inser-
tional mutagenesis to test for viability [18]. It is, there-
fore, possible that gene deletion can give misleading data
on the requirement of specific genes for virulence. Thus,
we conclude from our observations that expression of the
full length M135R gene product is not essential for viru-
lence in European rabbits. It would be interesting to
assess by transcription profiling (e.g., as described for
vaccinia virus [20,21]) whether the targeted deletion of
the myxoma virus M135R gene has an influence on the
expression of neighbouring genes.
Very recently, Morales et al. [14] reported the complete
genome sequence of a nonpathogenic myxoma virus strain
(6918) (see [17]) and found that it encoded thirty-two
amino acid substitutions plus six insertions or deletions
leading to four frame-shift mutations (plus two intergenic
region changes) compared to the parental Lausanne strain
of the virus (which was 99.95% identical in sequence). One
of these frame-shift mutations, within strain 6918, is
within the M135R gene and is identical to the change
observed within most of the recent Danish samples ana-
lysed. It is interesting to note that analysis of recent Portu-
guese isolates of myxoma virus found evidence of another
frame-shift mutation within a virulent strain of this virus
which also occurred at a homopolymeric region [22].
To analyse the similarity between the Danish samples
and the avirulent 6918 strain, five other regions of the
myxoma virus genomes from Danish samples with or
without the M135R insertion were amplified by PCR
and sequenced. These analyses showed that none of the
other frame-shift mutations were present in the Danish
samples although the deletion of a single T from within
the M138L/M139R intergenic region was a common
f e a t u r e( T a b l e3 ) .M o r a l e se ta l .[ 1 4 ]s u g g e s t e dt h a tt h e
frame-shift mutation within the M135R gene may be an
important determinant of the attenuation of the 6918
strain since, as described above, deletion of the gene
had lead to attenuation [8]. However, the properties of
the Danish samples would suggest that some other
sequence changes within the 6918 strain are responsible
for this phenotype. The critical change(s) could either
be amongst the insertions/deletions that are not present
in the Danish samples or within the changes leading to
the thirty-two different amino acid substitutions.
Conclusions
1) A sensitive and specific qPCR assay has been estab-
lished for myxoma virus.
2) An unusually high number of clinical cases of myx-
oma occurred in Denmark in 2007.
3) A high proportion of the Danish samples that were
analysed had a frame-shift mutation within the M135R
protein coding sequence which results in the expression
of a severely truncated product.
4 )T h ep r e s e n c eo ft h i ss a m ef r a m e - s h i f tm u t a t i o n
within an attenuated myxoma virus (6918) is not suffi-
cient to explain its attenuation.
5) Analysis of the effect of the frame-shift mutation
within the M135R gene, in isolation, on the virulence of
myxoma virus in European rabbits is warranted.
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